News
The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...
An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...
In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...
Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.
Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss ...
Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...
One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?
Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...
Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...
GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...
The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed for diabetes that are now being used to help people lose significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results